This image is released under a Resin block commemorating the development of the Moderna COVID-19 Vaccine
COVID-19 glass vaccine vial by Moderna Inc., encased in resin block, a commemorative object to mark the rapid development from beginnings to trial status, by Moderna Inc., USA, 2020
On 7 February 2020, Moderna produced the first clinical batch of their COVID-19 vaccine, also known as mRNA-1273. Their first batch came just under a month after the first genome sequence of COVID-19 was made publicly available on 10 January 2020. By 13 January 2020, Moderna’s vaccine was designed. Their clinical trial with human participants began on 13 March 2020. Eight months later, the company announced that their vaccine had achieved 94.5% efficacy.
Moderna, Inc’s COVID-19 vaccine is a mRNA vaccine. Messenger RNA (mRNA) puts the instructions in DNA into action. With the vaccine, it safely teaches our immune systems to create a response to COVID-19. It means that if someone encounters COVID-19, they have some protection against the virus. Researchers including those at Moderna have been researching mRNA vaccines for years. However, the COVID-19 pandemic is the first time this type of vaccine has been approved for clinical use.
In the United Kingdom, the Moderna vaccine was approved for emergency use on 8 January 2021. The first doses were used in Wales on 7 April 2021.
- Measurements:
-
overall: 105 mm x 105 mm x 27 mm,
- Object Number:
- 2021-1275/1
- type:
- commemorative block
